Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.

PubWeight™: 0.76^‹?›

🔗 View Article (PMID 27169565)

Published in BMC Cardiovasc Disord on May 11, 2016

Authors

Ling Li¹, Sheyu Li², Jiali Liu¹, Ke Deng³, Jason W Busse⁴^,5^,6, Per Olav Vandvik⁷^,8, Evelyn Wong⁹, Zahra N Sohani⁴^,10, Malgorzata M Bala¹¹^,12, Lorena P Rios¹³, German Malaga¹⁴, Shanil Ebrahim⁴^,5^,15^,16, Jiantong Shen¹, Longhao Zhang¹, Pujing Zhao¹, Qunfei Chen¹⁷, Yingqiang Wang¹⁸, Gordon H Guyatt⁴^,19, Xin Sun²⁰

Author Affiliations

1: Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China.
2: Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
3: West China school of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
4: Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
5: Department of Anesthesia, McMaster University, Hamilton, ON, Canada.
6: The Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON, Canada.
7: Norwegian Knowledge Centre for the Health Services, Oslo, Norway.
8: Department of Medicine, Innlandet Hospital Trust, Gjøvik, Norway.
9: Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
10: Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada.
11: Department of Hygiene and Dietetics, Jagiellonian University Medical College, Krakow, Poland.
12: Systematic Reviews Unit-Polish Cochrane Branch, Jagiellonian University Medical College, Krakow, Poland.
13: Internal Medicine Unit, Hospital Clinico FUSAT, Rancagua, Chile.
14: Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
15: Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, USA.
16: Department of Anaesthesia & Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
17: The Second Hospital of Lanzhou University, Lanzhou, China.
18: Department of Medical Administration, 363 Hospital, Chengdu, Sichuan, China.
19: Department of Medicine, McMaster University, Hamilton, ON, Canada.
20: Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, 37 GuoXue Xiang, Chengdu, 610041, Sichuan, China. sunx79@hotmail.com.

Associated clinical trials:

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3) | NCT00294723

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together (LEAD-2) | NCT00318461

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) | NCT01191268

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) (AWARD-2) | NCT01075282

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | NCT00849017

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes | NCT00838916

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) | NCT01126580

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes | NCT00960661

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes | NCT00839527

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-1) | NCT01064687

Evaluation of Exenatide in Patients With Diabetic Neuropathy | NCT00855439

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes | NCT00838903

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes | NCT00614120

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients | NCT00360334

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | NCT01620489

Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin | NCT00701935

Safety and Efficacy of Albiglutide in Type 2 Diabetes | NCT00849056

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus | NCT00935532

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone | NCT01512108

Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes | NCT01060059

Articles citing this ↘

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther (2016) 0.75

Articles cited by this ↗

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2015) 12.05

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2008) 6.91

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care (2008) 5.94

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 5.57

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med (2007) 4.56

GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol (2011) 3.54

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 3.51

GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol (2011) 3.44

GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol (2011) 3.30

GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol (2011) 3.02

GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol (2011) 2.83

Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol (2011) 2.69

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail (2014) 2.02

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care (2014) 1.61

Incretin-based drugs and the risk of congestive heart failure. Diabetes Care (2014) 1.60

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care (2014) 1.40

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res (2004) 1.37

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab (2012) 1.19

Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med (2011) 1.04

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care (2014) 1.03

Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther (2012) 1.01

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab (2013) 1.01

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia (2014) 0.97

Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol (2014) 0.97

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol (2015) 0.90

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J (2015) 0.88

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract (2015) 0.86

Cardiovascular safety and diabetes drug development. Lancet (2011) 0.84

Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. J Diabetes (2015) 0.82

Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). Diabetes Obes Metab (2012) 0.81

Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis. J Diabetes (2014) 0.79

Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis. Ann Med (2014) 0.78

The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. J Clin Pharm Ther (2013) 0.78

Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study. BMJ Open (2013) 0.78

Articles by these authors ⇆

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ (2016) 1.21

Guideline of guidelines: thromboprophylaxis for urological surgery. BJU Int (2016) 0.78

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep (2017) 0.76

Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome. Oncotarget (2017) 0.75